Boehringer attacks French HTA body's downgrading of Pradaxa
This article was originally published in Scrip
Following a review of the novel oral anticoagulants (NOACs) in the prevention of stroke and systemic embolism, France's health technology assessment body (HAS) has downgraded the "medical benefit" rating (SMR) of Boehringer Ingelheim's Pradaxa (dabigatran etexilate) from "important" to "moderate".
You may also be interested in...
The DIA Europe 2020 conference heard from regulators and health technology assessment bodies about the problems that can arise over poorly defined patient populations and a lack of comparator data when making reimbursement decisions.
Participants at a workshop on the EU’s proposed Pharmaceutical Strategy discussed affordability and drug shortages and called for more urgency on the draft HTA regulation.
Medical device and pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from EU’s single market and customs union at the beginning of 2021.